Ultra small particles of iron oxide (USPIO) ( DrugBank: Iron, Iron oxide )

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2006-001337-17-DE
(EUCTR)		25/09/200726/03/2007Characterisation of multiple sclerosis pathology by ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques[Charakterisierung der Multiple Sklerose Pathologie durch ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIPCharacterisation of multiple sclerosis pathology by ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques[Charakterisierung der Multiple Sklerose Pathologie durch ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIP Patients with Multiple Sclerosis (MS, N=90) and patients with a clinically isolated syndrome (ref. to as CIS in literature, i. e. not a clinically definite MS but a syndrome that may occur as first sign of MS early in the course, N=15) are planned to be investigated in the proposed clinical trial.
MedDRA version: 8.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis		Product Name: ultra small particles of iron oxide (USPIO)
Product Code: SH U 555 C
INN or Proposed INN: SH U 555 C
Other descriptive name: Ultrasmall particles of iron oxide		Max-Planck-Institute of PsychiatryNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		Germany